Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings?

Gilead Sciences (GILD) shares recently traded at $137.77, down 11.3% over the last six months versus a 13.1% gain for the S&P 500. Following its second-quarter earnings, the decline may prompt investors to reconsider whether the stock offers a buying opportunity or remains a portfolio risk. The lower share price has not materially improved the investment case. Gilead is not a poor business, but its operating trends fall short of the characteristics typically associated with stronger long-term investments. Revenue growth is the first concern. Sales increased at a 2.7% compounded annual growth rate over the past five years. Although any company can deliver a strong quarter or two, durable businesses generally produce sustained expansion over longer periods. Gilead’s modest sales growth raises questions about its long-term trajectory. Profitability has deteriorated more significantly. Adjusted operating margin declined by 34.2 percentage points over the same five-year period. This measure reflects profitability after core expenses, including marketing and research and development, while excluding various one-time costs. The decline is notable because revenue growth should ordinarily improve fixed-cost leverage and economies of scale. The adjusted operating margin was 9.7% over the trailing 12 months, indicating continued pressure on the expense base. Per-share earnings provide another warning. EPS fell 15.4% annually over five years even as revenue grew 2.7%. The divergence suggests Gilead became less profitable on a per-share basis as it expanded. At $137.77, the stock trades at 14.9 times forward earnings. That valuation appears fair, but the potential upside is not compelling relative to the possible downside. Investors may find stronger opportunities elsewhere, including a favored software and edge-computing pick. The combination of limited sales growth, contracting margins and declining EPS supports a cautious hold-or-sell stance rather than a strong buy.